Long-Term Psoriatic Arthritis Data for AbbVie’s Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports
Newly released data may provide a competitive edge over in-class competitor, Janssen’s Tremfya EXTON, Pa., December 21, 2022 /PRNewswire/ — Spherix Global Insights, a leading provider of market research, business intelligence, and advisory services to the global life sciences industry, has been tracking the evolution of the US psoriatic arthritis (PsA) market for seven years, including […]
Ardelyx’s Tenapanor (IBSRELA) Becomes a Relevant Player in the Irritable Bowel Syndrome with Constipation Market as the Company Awaits Important Regulatory News for the Drug in Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Surveyed nephrologists indicate enormous unmet need for new drugs to treat hyperphosphatemia and anticipate early adoption if the product is approved by the FDA EXTON, Pa., Dec 14, 2022 /PRNewswire/ – After receiving an unexpected Complete Response Letter (CRL) from the FDA in July 2021 for tenapanor (marketed as XPHOZAH) to treat hyperphosphatemia, Ardelyx pivoted […]
Aided by “Clean” FDA Label, US Dermatologists Report BMS’ Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights
Amgen’s Otezla likely to face the most immediate impacts of increased Sotyktu adoption EXTON, Pa., December 8, 2022 /PRNewswire/ — On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective TKY2 inhibitor available in the US to treat the disease. In October 2022, Spherix began […]
The European Medicines Agency’s Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis – A Cause for Concern? Spherix Investigates
Surveyed EU5 rheumatologists indicate newfound shaky perceptions of the JAK class, though whether overall brand share and use will be affected is still in question EXTON, Pa., December 2, 2022 /PRNewswire/ — On October 28, 2022, the European Medicines Agency’s (EMA) safety committee (PRAC) announced recommendations to minimize the risk of serious side effects when using […]
Bristol Myers Squibb’s Zeposia, AbbVie’s Skyrizi and Rinvoq shake up early IBD treatment market: report
The U.S. inflammatory bowel disease (IBD) market is seeing a shift in what drugs patients are offered for their first prescriptions. Doctors appear to be favoring the most recently approved drugs from the likes of Bristol Myers Squibb and AbbVie over older TNF therapies, according to a new report by Spherix Global Insights, a healthcare […]
FibroGen/Astellas’ EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, According to Spherix Global Insights
Findings are based on a bi-annual study of 258 European Union & United Kingdom nephrologists EXTON, Pa., December 6, 2022 /PRNewswire/ — After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021 for Roxadustat, FibroGen found success with partner Astellas in Europe. EVRENZO […]
With Approximately 45% of Eosinophilic Esophagitis Patients Going Undiagnosed, the Growth Opportunity for Sanofi/Regeneron’s Dupixent and Future Advanced Therapies Could Be Significant, According to Spherix
Surveyed US gastroenterologists and allergists agree a high unmet need remains, though treatment approach differs between groups EXTON, Pa., December 5, 2022 /PRNewswire/ – Sanofi/Regeneron significantly changed the EoE treatment landscape last May when the FDA approved Dupixent (dupilumab) to treat adult and pediatric patients suffering from eosinophilic esophagitis (EoE). Spherix Global Insights’ recent research […]
Bristol Myers, AbbVie drugs shake up first-line prescribing among gastroenterologists — report
Bristol Myers Squibb and AbbVie are changing up the inflammatory bowel disease (IBD) market with gastroenterologists, thanks to newer-to-market drugs Zeposia and Skyrizi, respectively. The two drugs have made big gains since 2021 in first-line prescriptions, according to Spherix Global Insights’ latest real world tracking report.
Spherix Global Insights and Cheeriodicals – Smiles for Hospitalized Children – 25 Years in the Making
Nearly 25 years ago, Spherix Global Insights’ CEO, Jennifer Robinson, and Cheeriodicals’ CEO, Gary Parisher, met when they entered the healthcare world as sales representatives for Genzyme’s new renal division. Robinson and Parisher were both excited and fortunate to join such a well-established biotech company, especially as Genzyme launched its first product in the renal […]
A New Horizon? Buyout Interest from J&J (Janssen), Sanofi, and Amgen
With one of the most promising autoimmune and rare disease product pipelines in the industry, it is no surprise that Horizon Therapeutics has attracted the attention as a potential acquisition target by three of the biggest players in the autoimmune space – Janssen, Sanofi, and Amgen. Who’s making moves? Given Spherix Global Insights’ deep expertise […]
